JP2024522184A5 - - Google Patents

Info

Publication number
JP2024522184A5
JP2024522184A5 JP2023575830A JP2023575830A JP2024522184A5 JP 2024522184 A5 JP2024522184 A5 JP 2024522184A5 JP 2023575830 A JP2023575830 A JP 2023575830A JP 2023575830 A JP2023575830 A JP 2023575830A JP 2024522184 A5 JP2024522184 A5 JP 2024522184A5
Authority
JP
Japan
Prior art keywords
alkyl
group
cycloalkyl
hydroxy
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522184A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032718 external-priority patent/WO2022261243A1/en
Publication of JP2024522184A publication Critical patent/JP2024522184A/ja
Publication of JP2024522184A5 publication Critical patent/JP2024522184A5/ja
Pending legal-status Critical Current

Links

JP2023575830A 2021-06-09 2022-06-08 Ｓｅｔｄ２阻害剤との併用療法 Pending JP2024522184A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208882P 2021-06-09 2021-06-09
US63/208,882 2021-06-09
PCT/US2022/032718 WO2022261243A1 (en) 2021-06-09 2022-06-08 Combination therapies with setd2 inhibitors

Publications (2)

Publication Number Publication Date
JP2024522184A JP2024522184A (ja) 2024-06-11
JP2024522184A5 true JP2024522184A5 (enExample) 2025-06-16

Family

ID=84425539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575830A Pending JP2024522184A (ja) 2021-06-09 2022-06-08 Ｓｅｔｄ２阻害剤との併用療法

Country Status (10)

Country Link
US (1) US20240299352A1 (enExample)
EP (1) EP4351552A4 (enExample)
JP (1) JP2024522184A (enExample)
KR (1) KR20240019241A (enExample)
CN (1) CN117794543A (enExample)
AU (1) AU2022288073A1 (enExample)
CA (1) CA3221071A1 (enExample)
IL (1) IL308868A (enExample)
MX (1) MX2023014663A (enExample)
WO (1) WO2022261243A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272379B2 (en) 2017-08-14 2025-11-01 Epizyme Inc Methods of treating cancer by inhibiting setd2
JP7627209B2 (ja) 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
CN121695288A (zh) 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法
WO2025034951A1 (en) * 2023-08-09 2025-02-13 Enanta Pharmaceuticals, Inc. Pharmaceutical compounds and compositions as c-kit kinase inhibitors
TW202532067A (zh) * 2023-12-13 2025-08-16 大陸商正大天晴藥業集團股份有限公司 含有吡唑環及雙環雜芳基的化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446064B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
WO2015150097A1 (en) * 2014-04-04 2015-10-08 Iomet Pharma Ltd Indole derivatives for use in medicine
US20170232030A1 (en) * 2014-08-13 2017-08-17 Epizyme, Inc. Combination therapy for treating cancer
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
IL272379B2 (en) * 2017-08-14 2025-11-01 Epizyme Inc Methods of treating cancer by inhibiting setd2
JP7627209B2 (ja) * 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
WO2020112872A1 (en) * 2018-11-30 2020-06-04 Epizyme, Inc. Methods of treating whsc1-overexpressing cancers by inhibiting setd2
CN121695288A (zh) * 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法

Similar Documents

Publication Publication Date Title
AU2020201321B2 (en) Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
IL307635A (en) Medicinal use of a cyclic peptide compound
US20090149511A1 (en) Administration of an Inhibitor of HDAC and an mTOR Inhibitor
JP2023541432A (ja) リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法
CA2725390C (en) Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
JP2019514854A5 (enExample)
RU2019126562A (ru) ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
JP2023514280A5 (enExample)
BR112021003467A2 (pt) composições de inibidores de cxcr4 e métodos de preparação e uso
RU2006146619A (ru) Лечение гемцитабином и ингибитором рецептора эпидермального фактора роста(egfr)
SG194045A1 (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
CN101677977A (zh) 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合
WO2009126537A1 (en) Administration of an inhibitor of hdac and an hmt inhibitor
IL295654A (en) Setd2 inhibitors and related methods and uses, including combination therapies
EP3888648A1 (en) Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy
HUP0203054A2 (hu) Farnezil protein transzferáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
RU2019138222A (ru) Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли
AU2020308814A1 (en) Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
RU2005140379A (ru) Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные
WO2019107386A1 (ja) 抗腫瘍剤
JP2005526794A5 (ja) ベンズイミダゾールおよびマイトジェン活性化およびｒｈｏキナーゼ阻害剤としてのその使用
PE20250609A1 (es) Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos
RU2006138864A (ru) Ингибиторы митотического кинезина
Abdo et al. Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy
CN114786674A (zh) Ahr抑制剂和pd1抑制剂抗体的组合及其在癌症治疗中的用途